Metopirone Esteve Pharmaceuticals (Metyrapone)

Metyrapone blocks the enzyme 11‑beta‑hydroxylase (CYP11B1) in the adrenal cortex, preventing the final step of cortisol production. This reduction in cortisol allows for dynamic testing of adrenal reserve and provides therapeutic cortisol lowering in conditions such as Cushing's syndrome.

The dosage of Metopirone is individualized by the prescribing clinician based on the specific indication, patient age, weight, and clinical response. Physicians determine the appropriate amount and schedule, and patients should follow the prescribed regimen without deviation.

Safety data for metyrapone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after careful assessment.

To request Metopirone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metopirone differs from other agents such as ketoconazole or osilodrostat by specifically inhibiting 11‑beta‑hydroxylase, whereas ketoconazole has broader antifungal and steroidogenic effects. Metopirone is often chosen for rapid cortisol reduction in diagnostic settings or when alternative agents are contraindicated.

Metopirone should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Metopirone is taken orally, usually as a tablet. The exact administration schedule—such as timing relative to meals—depends on the prescriber's instructions and the therapeutic goal, whether diagnostic or therapeutic.

The most serious risks include adrenal insufficiency, which can lead to life‑threatening cortisol deficiency, severe hypertension or hypotension, and rare hepatic dysfunction. Patients should be monitored closely for signs of these conditions, and any sudden symptoms should prompt immediate medical attention.

Metopirone is contraindicated in patients with known hypersensitivity to metyrapone or any of its excipients. Caution is also advised for individuals with uncontrolled hypertension, severe liver disease, or those who are pregnant or breastfeeding unless the benefits outweigh the risks.